Financial Comparison: Arrowhead Pharmaceuticals (ARWR) vs. Its Competitors
Arrowhead Pharmaceuticals (NASDAQ: ARWR) is one of 296 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Arrowhead Pharmaceuticals to similar companies based on the strength of its earnings, valuation, institutional ownership, risk, analyst recommendations, profitability and dividends.
This is a breakdown of recent recommendations for Arrowhead Pharmaceuticals and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Arrowhead Pharmaceuticals Competitors||765||3041||11223||227||2.72|
Arrowhead Pharmaceuticals presently has a consensus price target of $2.00, suggesting a potential downside of 45.21%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 36.03%. Given Arrowhead Pharmaceuticals’ peers stronger consensus rating and higher possible upside, analysts plainly believe Arrowhead Pharmaceuticals has less favorable growth aspects than its peers.
Valuation and Earnings
This table compares Arrowhead Pharmaceuticals and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Arrowhead Pharmaceuticals||$22.73 million||-$47.97 million||-5.53|
|Arrowhead Pharmaceuticals Competitors||$260.16 million||$66.28 million||-6.36|
Arrowhead Pharmaceuticals’ peers have higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Risk & Volatility
Arrowhead Pharmaceuticals has a beta of 1.92, suggesting that its stock price is 92% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals’ peers have a beta of 6.62, suggesting that their average stock price is 562% more volatile than the S&P 500.
This table compares Arrowhead Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Arrowhead Pharmaceuticals Competitors||-5,489.25%||-451.68%||-42.65%|
Insider and Institutional Ownership
20.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 4.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Comparatively, 16.4% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Arrowhead Pharmaceuticals peers beat Arrowhead Pharmaceuticals on 9 of the 12 factors compared.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company’s preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company’s pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.
Receive News & Ratings for Arrowhead Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.